Fatigue is a frequently reported and predominant symptom experienced by patients with inflammatory bowel disease (IBD) and its impact has been associated with poorer quality of life (QoL). The complex interplay between disease-related variables and potentially modifiable psychosocial factors in IBD-fatigue has yet to be unravelled.
SUMMARY Background
Fatigue is a frequently reported and predominant symptom experienced by patients with inflammatory bowel disease (IBD) and its impact has been associated with poorer quality of life (QoL). The complex interplay between disease-related variables and potentially modifiable psychosocial factors in IBD-fatigue has yet to be unravelled.
Aim
To evaluate the contribution of clinical, sociodemographic and psychosocial factors to the severity and impact of IBD-fatigue and QoL.
Method
In a cross-sectional study, 182 patients with IBD were recruited from three tertiary referral hospitals' out-patient clinics in London. Fatigue was assessed utilising the Inflammatory Bowel Disease-Fatigue Scale (IBD-F), the Multidimensional Fatigue Inventory (MFI); and QoL by the Inflammatory Bowel Disease Questionnaire (IBDQ). Patients completed self-report questionnaires evaluating emotional, cognitive and behavioural factors potentially correlated with fatigue. Sociodemographic data were collected. Disease-related and laboratory data were retrieved from patients' hospital electronic medical records. Result In hierarchical regression models, disease activity was the only clinical factor consistently associated with severity and impact of fatigue and QoL (P = 0.01). More negative fatigue perceptions were significantly associated with greater IBD-F1 scores (P = 0.01). When controlling for clinical factors (disease activity and anti-TNF therapy), negative perceptions of fatigue, and all-or-nothing and avoidance behaviours explained an additional 41% of the variance in fatigue impact (IBD-F2).
Conclusions
Apart from disease activity, emotional and behavioural factors and patients' negative fatigue perceptions may be key factors to be addressed. Further exploration of these factors in longitudinal and intervention studies may help to develop effective models of fatigue management.
Aliment Pharmacol Ther 2017; 45: 403-416
INTRODUCTION Symptoms of disabling and persistent fatigue are prevalent complaints within inflammatory, relapsing and remitting conditions. 1 Fatigue is one of the most frequently reported symptoms experienced by individuals with inflammatory bowel disease (IBD), with significantly higher fatigue severity scores being reported compared to healthy controls. 2 Although fatigue increases during periods of gastrointestinal inflammation, it also persists in some patients in whom disease is in clinical and endoscopic remission. 3 Prevalence of fatigue ranges between 44% and 86% in active IBD and 22-41% in those with quiescent disease. 4 Fatigue can be described as a mental and/or physical overwhelming sense of tiredness, weakness or exhaustion which is usually unrelieved by rest or sleep. 5 The subjective nature of fatigue makes it difficult to report, assess and understand by both patients and healthcare professionals. [6] [7] [8] Fatigue has been associated with poorer quality of life (QoL), 9 and fatigued individuals with ulcerative colitis (UC) and Crohn's disease (CD) show significantly greater work impairment than those without fatigue. 10 The aetiology of IBD-fatigue is still unclear. 3 Disease activity, 9, 11-13 anaemia [14] [15] [16] and inflammation 15 have been found to be predictive of fatigue, yet there is a considerable number of IBD patients with no apparent physiological underpinnings for their fatigue. 17 The focus of previous research on the relationship between fatigue and these clinical variables has limited the exploration of how these and other potentially modifiable factors interact with each other to exert their effect. 18 Fatigue has rarely been the primary outcome in intervention studies. 19, 20 Effective management strategies remain sparse and with only short-term effects of interventions being reported. [21] [22] [23] To develop interventions beneficial to patients, 24 it is important to shift from management of IBD aimed solely at treating inflammation and other clinical factors. 25 Working within a biopsychosocial model of care where clinical and psychosocial factors are identified and targeted alongside each other to restore patients' QoL may be more beneficial. [26] [27] [28] Initial data from studies exploring psychosocial interventions, 20 functional somatic syndromes 47 and irritable bowel syndrome. 48 The evaluation of the relationship between cognitive-behavioural variables and IBD-fatigue is thus of importance. This study aimed to evaluate the contribution of clinical, sociodemographic and psychosocial factors to the severity and impact of fatigue and QoL in patients with IBD. Unravelling the complex interplay between clinical and modifiable psychosocial factors, can aid in developing potentially effective interventions for the management of IBD-fatigue, and ultimately improve patients' QoL. Given the findings from studies in other long-term conditions, this study investigated whether (i) emotional (depression, anxiety, distress and stress), (ii) cognitive (illness perceptions and symptom beliefs) and (iii) behavioural factors (avoidance and all-or-nothing behaviours, and daytime sleepiness) are associated with severity and impact of fatigue and QoL.
METHODS

Study design and population
The study followed a cross-sectional design assessing the association between fatigue and clinical, sociodemographic and psychosocial factors. Participants were recruited between September 2015 and March 2016 from the IBD services (out-patient clinics and biologic infusion units) at three tertiary referral hospitals in London. Patients with a documented diagnosis of IBD, aged 18 and over, with sufficient command of written and spoken English to complete self-report questionnaires were considered eligible for inclusion. Exclusion criteria were known cognitive impairment, currently on intravenous iron therapy, pregnancy or childbirth within the last 6 months. The secondary outcome measure was health-related QoL as measured by the Inflammatory Bowel Disease Questionnaire (IBDQ). 59 The IBDQ is a disease-specific measure of overall physical, mental and social well-being in patients with CD and UC. The scale has 32 items scored on a 7-point Likert scale, higher scores signify better QoL.
Sociodemographic and clinical data collection
Predictors of the outcome variables. Based on findings in other conditions a decision was made to explore a number of emotional (anxiety and depression, stress and distress), cognitive (illness perceptions and symptom beliefs) and behavioural factors (avoidance and all-ornothing behaviours, and daytime sleepiness) as potential predictors of the outcome variables. The Hospital Anxiety and Depression Scale (HADS), 60 Cohen Perceived Stress Scale (PSS) 61 and the Inflammatory Bowel Disease-Distress Scale (IBD-DS) 62 were used to assess potential emotional factors associated with the outcome variables. The HADS was selected for this study as it was originally developed for physically ill patients and no items about somatic symptoms are included. 63 It is a widely used self-report instrument for assessing depression and anxiety in patients with medical illnesses 64 and it includes two subscales, anxiety and depression, each consisting of seven items (each scored 0-3). The two subscales are scored separately and higher scores indicate higher anxiety and depression respectively (maximum score for each = 21). The PSS was developed to examine the role of stress in disease. It measures self-perceived stressful situations and stress reactions on a cognitive and emotional level. The questionnaire contains 14 items, each is scored from 0 to 4; with a possible global score ranging from 0 to 56.
The IBD-DS is a newly developed scale designed to identify and measure disease-related distress in IBD in the last 3 months. 65 The scale consists of a number of questions which are scored on a 6-point Likert scale, ranging from 'Not distressing' to 'Highly distressing', with higher scores indicating higher distress. Cognitive factors were assessed using The Brief Illness Perceptions Questionnaire (BIPQ) 66 and the cognitive subscales of the Cognitive Behavioural Response to Symptoms Questionnaire (CBSQ). 33 The study utilised a modified version of the BIPQ consisting of eight items: five assess cognitive illness representations (consequences, timeline, personal control, treatment control and identity); two emotional representations (concern and emotions) and one item assesses illness comprehensibility. The open-ended response item assessing the causal representation of fatigue was excluded from the questionnaire. In line with recommendations from the authors of the scale, 67 to make the questionnaire more relevant to the IBD patient group, the word 'illness' was replaced with 'fatigue'. This has been done in other studies [68] [69] [70] assessing clinical and psychosocial outcomes in patients with long-term conditions to make the questions more specific to their topic of research. Each item is rated on a 0-10 scale. Given the known limitations of assessing content validity with single item measures 71 and the increased risk of type 1 errors when using multiple testing, 72 a total sum Fatigue perception score (ranging 0-80) was calculated as opposed to calculating scores for the individual subscales. Higher sum scores indicated more negative, unhelpful representations of IBD-fatigue. The CBSQ measures patients' cognitive and behavioural responses to their symptoms (of fatigue). It contains 40 items measured on a 5-point Likert scale. Items are added to form five cognitive subscales (fear avoidance, embarrassment avoidance, damage beliefs, symptom focus and catastrophising about symptoms). Higher scores indicate more negative cognitive responses to fatigue symptoms. Behavioural factors associated with fatigue and QoL were assessed with the behavioural subscales of the CBSQ (resting and avoidance of activity and all-or-nothing behaviour) and the Epworth Sleepiness Scale (ESS). 73 The ESS measures a subject's level of daytime sleepiness by asking subjects to rate their chance of falling asleep on a scale of 0-3 in eight soporific situations, higher scores indicate higher propensity of falling asleep during the day (maximum score = 24). The scale provides an assessment of interference of sleepiness during the day. 74 
Ethical considerations
The study was approved by the United Kingdom National Research Ethics Service -London Bridge Committee (15/LO/1081). Eligible patients were provided with a Patient Information Sheet explaining the nature and aims of the study. Patients had the opportunity to take the questionnaires home and return them by post to fully consider their participation in the study and what participation in the study involved. Signed informed consent was returned with the questionnaires by post. All participants were allocated a study number to protect their anonymity.
Statistical methods
Statistical analyses were performed using SPSS version 22 (Armonk, NY: IBM Corp.). Missing data analyses were performed to assess extent and patterns of missing data for the study. Count variables were created for each of the scales (cut-off of 80%), mean and total scores were computed for each of the items. Overall 6% of all values were missing, 92% of the 182 patients had at least one missing value in their responses and 72% of the variables had at least one missing value. Multiple imputations were selected as a method of handling missing data (five imputations), chosen because of its flexibility and generality, its effectiveness with moderate sample sizes 75 and its previous application in medical studies. 76 However, as no significant differences were found between the groups, the data were analysed as a single group. Utilising G power 3.1.9.2 post hoc analysis, 77 it was estimated that with a sample size of 182 respondents and an alpha level P = 0.01 the statistical tests would be sufficiently powered to detect a moderate effect size. 78 Unadjusted associated correlations and differences between independent variables and fatigue levels (as measured by the IBD-F and MFI) and QoL (IBD-Q) were calculated using Pearson product-moment correlation coefficient for continuous variables, and independent samples t-tests and one-way between subjects ANOVAs for categorical variables. Factors associated with the outcomes in univariate analyses (P < 0.10) were then included in multivariate regression analyses to identify independent predictors of fatigue and QoL. All regression models were fitted after testing assumptions were met for the variables involved. 79 significance in multivariable analysis was set at P < 0.01.
RESULTS
Total of n = 414 patients were approached for inclusion in the study. Of these 182 patients provided informed consent and returned the completed questionnaires via post (44% response rate). The sociodemographic and clinical data of participants are presented in Table 1 . Data for those who declined consent could not be retrieved. Of those who completed the questionnaires (n = 182), 57% were female, 69% worked full time and their median age was 37.0 years (range 20-83 years). The majority (64%) of participants had CD, with a median of 12 years since diagnosis of IBD. Of the 88% of patients taking medication, 38% were on biologic medication (anti-TNFs or vedolizumab), and 4.9% (n = 9) patients had a stoma. Of those without a stoma n = 45 (26%) had active disease and n = 128 (74%) were in remission according to the DAI scores. Where data were available (n = 174), following the European Crohn's and Colitis Organisation guidelines for the management of anaemia in IBD 83 (<12 g/dL for adult women and <13 g/ dL for adult men), 17% of participants were anaemic.
Univariate analysis
The results of univariate analyses are shown in Tables  S1-S3 . Pearson product-moment correlations were calculated to assess univariate associations between sociodemographic, clinical and psychosocial factors and fatigue (IBD-F1, IBD-F2, MFI) and QoL (Table S1 ). Disease activity was significantly associated with fatigue and QoL across all scales. In addition, faecal calprotectin (r = 0.47, P < 0.001) and platelets (r = À0.15, P = 0.03) were significantly associated with QoL. No other sociodemographic or clinical variables were significantly related to fatigue or QoL. Emotional, cognitive and behavioural variables had positive significant correlation with both severity (IBD-F1 and MFI) and impact of fatigue (IBD-F2) and QoL, showing moderate to large effect sizes. Independent samples t-tests were computed to assess the differences in fatigue and QoL scores between dichotomous sociodemographic and clinical variables (Table S2, One-way between groups ANOVAs were computed to assess differences between fatigue and QoL according to sociodemographic and clinical predictor variables with more than two categorical groups (Table S3 ). There was a significant difference in fatigue and QoL according to employment, education, marital and smoking status. Furthermore, there were significant differences in fatigue (MFI) and QoL according to CD diagnosis and living alone respectively (P < .10).
Multivariable analysis
Factors associated with severity of fatigue (IBD-F1 and MFI). Significant factors in univariate analyses in respect to severity of fatigue (P < 0.10) were examined in two separate regression models for the IBD-F1 and the MFI (see Table 2 ). Disease activity (P = 0.01) was significantly positively associated with fatigue, explaining 21% of the variance in severity of fatigue scores. In the second block emotional, cognitive and behavioural variables were added, which significantly improved the predictive validity of the model, F inc (13, 147) = 9.78, P < 0.001, explaining 54% of the variance in severity of fatigue scores. More negative fatigue perceptions were significantly associated with greater IBD-F1 scores. After adjusting for psychosocial variables, disease activity (b = 0.77, P = 0.18) was no longer significantly associated with severity of fatigue (b = 0.11, P = 0.15).
Sociodemographic and clinical factors explained 24% of the variance in severity of fatigue assessed with the MFI general fatigue scale. Female gender, taking anti-TNF, disease activity and doing less than 30 min of exercise per week was associated with significantly greater fatigue scores. After adding emotional, cognitive and behavioural variables and controlling for sociodemographic and clinical factors, there was a significant change in the model F inc (13, 145) = 8.78, P < 0.001. Similarly to the IBD-F1, the fully adjusted model explained more than half (54%) of the variance in severity of fatigue. More negative fatigue perceptions were significantly associated with greater fatigue scores (MFI). Female gender, disease activity, anti-TNF and exercise were no longer significant after adjusting for psychosocial variables (P > 0.01).
Factors associated with impact of fatigue (IBD-F2) on individuals' lives. Significant factors in univariate analyses in respect to impact of fatigue assessed with the IBD-F2 (P < 0.10) were examined in a two-block hierarchical regression model (Table 2) . Block 1 including sociodemographic and clinical factors (education to 16, education to 18, retired, not working/housekeeping, female gender, current 5-ASAs, current anti-TNFs, disease activity, exercise <30 min per week and current steroids) explained 32% of the variance in impact of fatigue on daily activities. Disease activity, taking anti-TNF and not working/housekeeping were all independently significantly associated with greater negative impact of fatigue on daily activities. Adding emotional, cognitive and behavioural factors in block 2 significantly improved the model F inc (13, 150) = 21.62, P < 0.001. The model once fully adjusted for sociodemographic, clinical and psychosocial factors explained 73% of the variance in IBD-F2 impact of fatigue scores. More negative fatigue perceptions, all-or-nothing and avoidance behaviours were significantly associated with greater impact of fatigue on daily activities. After adjustment for psychosocial variables, not working, anti-TNF and higher disease activity were no longer significantly associated with impact of fatigue (P > 0.01).
Factors associated with IBD-specific QoL (IBDQ). Significant factors in univariate analyses in respect to IBD-specific QoL were examined in a hierarchical regression model (Table 3) . Sociodemographic and clinical factors were entered in block 1. Disease activity (P < 0.001) and currently taking steroids (P = 0.01) were significantly associated with worse QoL, explaining 42% of the model. In block 2, the addition of emotional, cognitive and behavioural variables significantly increased the validity of the model, F inc (13, 141) = 7.96, P < 0.001, with the fully adjusted model explaining 64% of the variance in QoL. Higher levels of IBD-related distress (p = 0.01) was significantly associated with diminished QoL. In the fully adjusted model disease activity (b = À1.20, P < 0.001) and currently taking steroids (b = À7.21, P < 0.001) were still significantly independently associated with diminished QoL.
DISCUSSION
This study aimed to investigate factors associated with severity and impact of both fatigue on daily activities, and QoL in patients with IBD. Specifically, it investigated whether modifiable emotional, cognitive and behavioural factors, shown to be associated with fatigue in other longterm conditions, 33, 35, 84 were also related to fatigue in patients with IBD. Potentially identifying parallels and drawing from existing treatment models in other conditions, can aid in uncovering processes of fatigue that can be applied trans-diagnostically across different conditions, [85] [86] [87] and ultimately in synthesising new constructs to target in intervention research in IBD. 31 The results of the study showed emotional, cognitive and behavioural factors were associated with fatigue and QoL above and beyond the influence of sociodemographic and clinical factors. Negative fatigue perceptions were significantly associated with severity of fatigue. Negative fatigue perceptions, all-ornothing and avoidance behaviours were significantly associated with impact of fatigue. Higher levels of IBD-related distress were significantly associated with worse QoL. Disease activity was the only clinical factor consistently independently associated with severity and impact of fatigue and QoL. While some factors such as female gender, anti-TNFs, doing less than 30 min of exercise per week and not being in employment were significantly associated with severity and impact of fatigue in univariate analysis, the associations were no longer significant in the fully adjusted multivariable regression analysis. Finally, disease activity together with currently taking steroids was significantly associated with worse QoL in both partly and fully adjusted models.
In line with findings from other clinical out-patient 13 and population-based 11 studies, the results from the present study confirmed disease activity as the most consistent independent factor related to fatigue and QoL. This indicates the management of active disease, through adequate medical and/or surgical therapy, as the first line of intervention for patients with IBD-fatigue. 18 In addition, the study corroborates recent findings from longitudinal observational findings suggesting that anti-TNF use is linked to more severe fatigue 12 and that cessation of biologic therapy is associated with a reduction in fatigue. 13 It is possible that biologics have already been efficacious in managing the inflammation and potentially improving fatigue at the point of cessation. 88 This finding is in contrast with pharmacological trials presenting a reduction in fatigue symptoms in patients taking infliximab 19, 21 and adalimumab. 89 However, patients taking anti-TNFs may have more severe and/or active disease, potentially suggesting disease activity as a confounding variable in this relationship. 90 Consistent with other studies, 14, 17, 91 no significant correlations were found between fatigue and clinical factors known to predict fatigue such as anaemia [14] [15] [16] and iron deficiency. 92 This lack of association has a number of possible explanations. Patients were recruited from tertiary referral centres where disease is closely monitored and managed through routine blood tests and only 17% were anaemic. Extensive missing data for ferritin (41%) and B12 (42%) levels may have limited the ability to draw conclusions on these parameters. Overall, these findings add to the evidence suggesting that, despite centrality of anaemia in fatigue symptoms, 93 there is a considerable proportion of patients where fatigue cannot be explained by clinical factors alone, and employment of non-pharmacological management may be required once disease activity has been addressed.
The bidirectional link between depression and fatigue in patients with IBD 9, 13 has been previously reported.
Data from this study highlight the importance of other relatively unexplored psychosocial factors in the IBDfatigue. Indeed, evidence from this study and studies in other long-term condition 33, 94 suggest that individuals with more negative perceptions about their fatigue, that is, feeling of not having control over their symptoms, and who engage in maladaptive behavioural coping strategies (daytime naps) will experience higher levels of fatigue. Likewise, the associations between negative perceptions of fatigue, avoidance and all-or-nothing behaviours and impact of fatigue (measured by the IBD-F2), 53 may further influence the coping strategies patients employ. 95 While various clinical and sociodemographic factors may go some way to account for presence and severity of fatigue, they cannot fully explain it. Findings from this study indicate that patients' subjective interpretation and responses to symptoms of fatigue, may determine its impact on their lives. Evidence from other chronic conditions, where fatigue is one of the symptoms, for example multiple sclerosis 45 or cancer, 96, 97 highlight the necessity for a paradigm shift in its management from strategies solely or predominantly focused on physical health towards an integrated approach assessing and targeting a range of factors according to patients' needs. 98 In instances where the fatigue is evidently related to a disease flare or other clinical problems, medical or surgical therapy may be beneficial. However, where there is no apparent explanation for fatigue, exploring psychosocial factors contributing to the onset and perpetuation of fatigue may be of value. 99 It is important to regularly assess IBD patients for fatigue and to try and identify its possible cognitivebehavioural associates. This could be the starting point in employing a holistic and systematic strategy for fatigue management. 3 
Limitations
The findings of the study should be considered in the light of several limitations. Due to the cross-sectional study design, causality between the different factors and fatigue cannot be inferred. Longitudinal designs would allow for more robust temporal associations between clinical and psychosocial factors to be assessed, together with an analysis of mediating factors. The use of patient self-report DAI scores when clinician-reported outcomes were not available may have resulted in incomplete or inaccurate data on remission status. 100 Although selfreported DAIs are often used in research studies, 10, 11 nevertheless, it is best practice for clinicians to complete them after obtaining information from the patients. 101 Furthermore, the extensive missing data for faecal calprotectin meant that this could not be utilised as an indicator of disease activity for the entire sample. Similarly, the study was not funded for additional blood tests unless they were indicated clinically. The collection of bloods upon questionnaire completion in future studies would minimise issues with missing clinical data encountered in this study. The significant correlation between QoL, fatigue and psychosocial factors may indicate a cross-validation between overlapping measures, longitudinal findings are therefore needed to reach more definitive conclusions on fatigue pathways. Recruitment from clinics and biologic infusion units at tertiary referral centres may indicate a sub-set of the IBD population, where the disease is closely monitored and well-managed. The moderate sample size precluded exploration of the differences according to diagnosis phenotype, potentially limiting the generalisability of the findings specifically to UC and CD populations.
CONCLUSIONS
The identification of psychosocial variables that predict fatigue over and above sociodemographic and clinical variables, emphasises the importance of conducting research on factors potentially amenable to modification. The study findings indicate that emotional and behavioural factors and patients' negative fatigue perceptions, may be the key factors to be addressed, possibly through psychological therapy. Further exploration of these factors in longitudinal and intervention studies may help to develop cognitive-behavioural models of fatigue management.
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